ALX Oncology (NASDAQ:ALXO) Earns Overweight Rating from Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday,Benzinga reports. Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a report on Wednesday. Three investment analysts have […]

Leave a Reply

Your email address will not be published.

Previous post Genesis Energy (NYSE:GEL) Completes Offering of Senior Notes due 2033
Next post CACI International (NYSE:CACI) Raised to Strong-Buy at TD Cowen